Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2018
Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2018
SUMMARY
Beta Nerve Growth Factor (Beta NGF or NGF) - Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI.
Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies.The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 4 and 1 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Ophthalmology, Dermatology, Hematological Disorders, Immunology and Metabolic Disorders which include indications Osteoarthritis Pain, Cancer Pain, Low Back Pain, Pain, Amyotrophic Lateral Sclerosis, Cardiac Arrest, Diabetic Neuropathy, Glaucoma, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Keratitis, Lung Transplant Rejection, Myocardial Infarction, Optic Nerve Injury, Parkinson's Disease, Peripheral Nerve Injury, Post-Operative Pain, Pressure Ulcers, Retinitis Pigmentosa (Retinitis), Sicca Syndrome (Sjogren) and Sickle Cell Disease.
The latest report Beta Nerve Growth Factor - Pipeline Review, H2 2018, outlays comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Beta Nerve Growth Factor (Beta NGF or NGF) - Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI.
Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies.The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 4 and 1 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Ophthalmology, Dermatology, Hematological Disorders, Immunology and Metabolic Disorders which include indications Osteoarthritis Pain, Cancer Pain, Low Back Pain, Pain, Amyotrophic Lateral Sclerosis, Cardiac Arrest, Diabetic Neuropathy, Glaucoma, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Keratitis, Lung Transplant Rejection, Myocardial Infarction, Optic Nerve Injury, Parkinson's Disease, Peripheral Nerve Injury, Post-Operative Pain, Pressure Ulcers, Retinitis Pigmentosa (Retinitis), Sicca Syndrome (Sjogren) and Sickle Cell Disease.
The latest report Beta Nerve Growth Factor - Pipeline Review, H2 2018, outlays comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)
- The report reviews Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Beta Nerve Growth Factor (Beta NGF or NGF) - Overview
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Fujimoto Pharmaceutical Corp
MedImmune LLC
MimeTech Srl
Pfizer Inc
Regeneron Pharmaceuticals Inc
Serometrix LLC
Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles
ASP-6294 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-7352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Activate NGF Beta for Optic Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NGF for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones
Featured News & Press Releases
Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints
Jul 20, 2018: Pfizer and Eli Lilly report positive results from Phase III tanezumab
Aug 17, 2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis
Jun 13, 2017: Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab
Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs
May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
Mar 23, 2015: Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab
Mar 12, 2012: FDA Panel Recommends Development Of NGF Inhibitors
Dec 27, 2010: FDA Halts Development Of Regeneron’s Pain Drug
Jul 19, 2010: Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program
Jun 23, 2010: Pfizer Suspends Osteoarthritis Clinical Program For Tanezumab
May 12, 2010: Regeneron Provides Initial Data On REGN475
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Beta Nerve Growth Factor (Beta NGF or NGF) - Overview
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Fujimoto Pharmaceutical Corp
MedImmune LLC
MimeTech Srl
Pfizer Inc
Regeneron Pharmaceuticals Inc
Serometrix LLC
Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles
ASP-6294 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-7352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Activate NGF Beta for Optic Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NGF for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones
Featured News & Press Releases
Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints
Jul 20, 2018: Pfizer and Eli Lilly report positive results from Phase III tanezumab
Aug 17, 2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis
Jun 13, 2017: Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab
Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs
May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
Mar 23, 2015: Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab
Mar 12, 2012: FDA Panel Recommends Development Of NGF Inhibitors
Dec 27, 2010: FDA Halts Development Of Regeneron’s Pain Drug
Jul 19, 2010: Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program
Jun 23, 2010: Pfizer Suspends Osteoarthritis Clinical Program For Tanezumab
May 12, 2010: Regeneron Provides Initial Data On REGN475
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Astellas Pharma Inc, H2 2018
Pipeline by Fujimoto Pharmaceutical Corp, H2 2018
Pipeline by MedImmune LLC, H2 2018
Pipeline by MimeTech Srl, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by Serometrix LLC, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Astellas Pharma Inc, H2 2018
Pipeline by Fujimoto Pharmaceutical Corp, H2 2018
Pipeline by MedImmune LLC, H2 2018
Pipeline by MimeTech Srl, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Pipeline by Serometrix LLC, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Astellas Pharma Inc
Fujimoto Pharmaceutical Corp
MedImmune LLC
MimeTech Srl
Pfizer Inc
Regeneron Pharmaceuticals Inc
Serometrix LLC
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Astellas Pharma Inc
Fujimoto Pharmaceutical Corp
MedImmune LLC
MimeTech Srl
Pfizer Inc
Regeneron Pharmaceuticals Inc
Serometrix LLC
